M. Letsch

Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers

A. Bajo, A. Schally, J. Varga, 2003, Proceedings of the National Academy of Sciences of the United States of America.

Effective treatment of experimental androgen sensitive and androgen independent intraosseous prostate cancer with targeted cytotoxic somatostatin analogue AN-238.

A. Schally, K. Szepesházi, G. Halmos, 2004, The Journal of urology.

Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.

A. Schally, K. Szepesházi, A. Nagy, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Inhibition of proliferation of PC‐3 human prostate cancer by antagonists of growth hormone–releasing hormone: Lack of correlation with the levels of serum IGF‐I and expression of tumoral IGF‐II and vascular endothelial growth factor

A. Schally, M. Krupa, F. Hébert, 2002, The Prostate.

Targeted chemotherapy with cytotoxic bombesin analogue AN‐215 inhibits growth of experimental human prostate cancers

R. Vessella, E. Corey, A. Schally, 2006, International journal of cancer.

Antagonists of growth hormone-releasing hormone (GH-RH) enhance tumour growth inhibition induced by androgen deprivation in human MDA-Pca-2b prostate cancers.

A. Schally, K. Groot, J. Varga, 2004, European journal of cancer.

Lipopeptide antagonists of growth hormone-releasing hormone with improved antitumor activities.

A. Schally, K. Groot, Gabor L. Toller, 2006, Proceedings of the National Academy of Sciences of the United States of America.